Jay Kozlowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6199850/publications.pdf

Version: 2024-02-01

		1478505	1199594	
13	135	6	12	
papers	citations	h-index	g-index	
13	13	13	320	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients. Journal of Pharmacy Practice, 2023, 36, 542-547.	1.0	2
2	Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events. Vascular Medicine, 2022, 27, 382-384.	1.5	2
3	Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism. American Journal of Cardiology, 2021, 159, 100-106.	1.6	1
4	Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registryâ€based cohort study. Journal of Thrombosis and Haemostasis, 2020, 18, 2025-2030.	3.8	6
5	Periprocedural Bridging Anticoagulation: Measuring the Impact of a Clinical Trial on Care Delivery. American Journal of Medicine, 2019, 132, 109.e1-109.e7.	1.5	7
6	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. Journal of Thrombosis and Thrombolysis, 2017, 43, 283-288.	2.1	22
7	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. Blood Advances, 2017, 1, 2536-2540.	5.2	7
8	Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. Implementation Science, 2017, 12, 87.	6.9	18
9	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. Journal of Thrombosis and Thrombolysis, 2016, 42, 566-572.	2.1	6
10	The changing characteristics of atrial fibrillation patients treated with warfarin. Journal of Thrombosis and Thrombolysis, 2015, 40, 488-493.	2.1	4
11	Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). Journal of Thrombosis and Thrombolysis, 2014, 37, 171-176.	2.1	12
12	The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQI2 Experience. Thrombosis Research, 2014, 134, 294-299.	1.7	35
13	Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). Journal of Thrombosis and Thrombolysis, 2013, 35, 10-14.	2.1	13